New Novartis thin-strip OTCs?
This article was originally published in The Tan Sheet
Executive Summary
Novartis and Adhesive Research's ARx division are expanding their work on developing Thin Strip offerings and have broken ground on a new facility that will be used to manufacture products employing the technology, the firms announce May 19. ARx Division already supports six thin film products, including Triaminic Thin Strips and Theraflu Thin Strips, both introduced by Novartis (1"The Tan Sheet" April 26, 2004, p. 13). ARx is the exclusive developer and supplier of active films for Novartis, and plans to launch 20 new products over the next three years. The firm is also developing a 25,000 square-foot facility, to be located on the ARx campus in Glen Rock, Penn. Novartis' launch of its thin strip products is "just the beginning of a relationship that will benefit from this new state-of-the-art facility"...
You may also be interested in...
Novartis Expects Thin Strips Technology To Drive OTC Cough/Cold Sales
Novartis Consumer Health is gearing up to launch new cough/cold products using a Thin Strips dosage form this summer
Executives On The Move: Changes At The Top At Enzolytics, Dyne Therapeutics And Seres Therapeutics
Recent moves in the industry include new chief financial officers at LENZ Therapeutics and Botanix Pharmaceuticals, plus new chief medical officers at Vigil Neuroscience and Voyager Therapeutics.
Israel's Gamida Cell Survives By Selling To Lender
Having finally secured US approval for Omisirge, Gamida was hoping to bag a strategic partner for the cell therapy. A year on, no suitable partner has been identified and the firm is delisting from the NASDAQ and going private.